{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T19:49:39Z","timestamp":1649188179356},"reference-count":19,"publisher":"Georg Thieme Verlag KG","issue":"04","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1055\/a-1593-8205","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T23:34:46Z","timestamp":1644881686000},"page":"157-164","source":"Crossref","is-referenced-by-count":0,"title":["Medikament\u00f6se Therapie der Demenz"],"prefix":"10.1055","volume":"147","author":[{"given":"Mareike","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"von Arnim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1159\/000091790","article-title":"3-Year Study of Donepezil Therapy in Alzheimer\u2019s Disease: Effects of Early and Continuous Therapy","volume":"21","author":"B Winblad","year":"2006","journal-title":"Dem Geriatr Cogn Disord"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-53875-3","volume-title":"S3-Leitlinie Demenzen: Interdisziplin\u00e4re S3-Praxisleitlinien","author":"DGPPN, DGN","year":"2017","edition":"1. Aufl."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"CD003154","DOI":"10.1002\/14651858.cd003154.pub6","article-title":"Memantine for dementia","volume":"3","author":"R McShane","year":"2019","journal-title":"Cochrane Data Syst Rev"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e0183586","DOI":"10.1371\/journal.pone.0183586","article-title":"Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis","volume":"12","author":"R Chen","year":"2017","journal-title":"PLoS ONE"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/925702","article-title":"Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer\u2019s Disease: A Review of Clinical Trials","author":"I Molino","year":"2013","journal-title":"Sci World J"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1007\/s40263-017-0459-3","article-title":"Pharmacotherapy for Vascular Cognitive Impairment","volume":"31","author":"M Farooq","year":"2017","journal-title":"CNS Drugs"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5315098","article-title":"Increased Risk of Dementia in Patients with Antidepressants: A Meta-Analysis of Observational Studies","author":"Y Wang","year":"2018","journal-title":"Behavioral Neurology"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1192\/bjp.bp.114.153684","article-title":"Behavioral and psychological symptoms in dementia and the challenges for family carers","volume":"208","author":"A Feast","year":"2016","journal-title":"Brit J Psychiatry"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.3389\/fphar.2020.01168","article-title":"Pharmacotherapy of Behavioral and Psychological Symptoms of Dementia: State of the Art and Future Progress","volume":"11","author":"R Magierski","year":"2020","journal-title":"Front Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/cns.12484","article-title":"Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer\u2019s Disease and Dementia with Lewy Bodies","volume":"22","author":"J Cummings","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3892\/etm.2018.7129","article-title":"Cholinesterase inhibitors and memantine for Parkinson\u2019s disease dementia and Lewy body dementia: A meta\u2011analysis","volume":"17","author":"Y Meng","year":"2018","journal-title":"Exp Ther Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.2174\/156720512803569037","article-title":"Antipsychotic Use and Mortality Risk in Community-Dwelling Alzheimer\u2019s Disease Patients: Evidence for a Role of Dementia Severity","volume":"9","author":"V Gardette","year":"2012","journal-title":"Curr Alzheimer Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/nmt-2019-0036","article-title":"Antipsychotics in the management of behavioral and psychological symptoms of dementia: maximizing gain and minimizing harm","volume":"10","author":"R Tampi","year":"2020","journal-title":"Neurodegener Dis Manag"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1532-5415.2008.01737.x","article-title":"Anticholinergic Activity of 107 Medications Commonly Used by Older Adults","volume":"56","author":"M Chew","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13195-021-00867-8","article-title":"Efficacy and safety of pharmacotherapy for Alzheimer\u2019s disease and for behavioural and psychological symptoms of dementia in older patients with moderate and severe functional impairments: a systematic review of controlled trials","volume":"13","author":"M Seibert","year":"2021","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/nejmoa061240","article-title":"Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer\u2019s Disease","volume":"355","author":"L Schneider","year":"2006","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"J Sevigny","year":"2016","journal-title":"Nature"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody","volume":"13","author":"C Swanson","year":"2021","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e12179","DOI":"10.1002\/trc2.12179","article-title":"Alzheimer\u2019s disease drug development pipeline","volume":"7","author":"J Cummings","year":"2021","journal-title":"Alzheimers Dement"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1593-8205.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T23:36:05Z","timestamp":1644881765000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1593-8205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":19,"journal-issue":{"issue":"04","published-online":{"date-parts":[[2022,2,14]]},"published-print":{"date-parts":[[2022,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1593-8205","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}